OCE Oncology News
A monthly newsletter for oncology/hematology fellows, junior faculty and scientists
A monthly newsletter for oncology/hematology fellows, junior faculty and scientists
Learn more about a 56-year-old woman diagnosed with well-differentiated papillary mesothelioma, and how she was diagnosed and properly treated.
Valerae Lewis, M.D., is a leader in the field of orthopedic oncology and chairs MD Anderson’s Orthopaedic Oncology department. Here, she shares what led her…
On May 16, 2024, the FDA granted accelerated approval to tarlatamab-dlle (Imdelltra, Amgen, Inc.) for extensive stage small cell lung cancer.
Enhancing DEI in Clinical Research: Strategies Used by Clinical Investigators
NICE recommends Oncotype DX to guide chemotherapy decisions in early-stage, HR-positive, HER2-negative breast cancer involving up to 3 positive nodes.
Genome-driven precision oncology has revolutionized cancer treatment and opened doors to tissue-agnostic precision medicine. Kummar et al.’s study confirms the effectiveness of neurotrophic receptor …
Here, we summarize results from a phase II trial assessing the safety and efficacy of acalabrutinib in combination with lenalidomide and rituximab in patients with…
NICE recommends Oncotype DX to guide chemotherapy decisions in early-stage, HR-positive, HER2-negative breast cancer involving up to 3 positive nodes.
Although the sample size for this trial was small, data still highlight a potential benefit with nivolumab in dMMR uterine and ovarian cancers.
Two studies provide new insights on the effects of vaginal oestrogen therapy and physical exercise to tackle sexual impairment